Drug Reference for FDA Approved Migraine Drugs @ Neurotransmitter.net
Generic Name: Database Search Links: |
Initial Approval: Product Label : |
Indications: |
Possible Mechanisms of Action: Aspirin (acetylsalicylic acid) acetylates vascular COX-2, which causes it to catalyze the synthesis of aspirin-triggered 15-epi-lipoxin intermediates rather than the synthesis of prostaglandin intermediates (3). Aspirin is also an irreversible inhibitor of cyclooxygenase-1 (COX-1) (4). Caffeine is a competitive antagonist at A1 and A2A adenosine receptors (5). The drug is also a nonselective phosphodiesterase inhibitor; however, normal consumption of caffeine is not likely to induce this effect (6). |
Chemical Classes: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of almotriptan have not been established for cluster headache, which is present in an older, predominantly male population. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Product Label : Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Classes: |
Generic Name: IUPAC Name
(caffeine)
: Common Chemical Name (ergotamine tartrate): Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Ergotamine is an agonist at serotonin 5-HT1A (8), 5-HT1B (8), 5-HT1D (8), 5-HT2A (9), 5-HT2B (9), 5-HT2C (9), 5-HT5A (10), and 5-HT6 (11) receptors. Ergotamine also binds relatively weakly to serotonin 5-HT1F receptors (12), alpha-2A-adrenoceptors (13), and alpha-2B-adrenoceptors (13). In addition, ergotamine may accelerate the transport of glutamate mediated by hGluT-1 (19). |
Chemical Class: PubChem 2D Structure: |
Generic Name: Common Chemical Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: Major Metabolites: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Eletriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of eletriptan have not been established for cluster headache, which is present in an older, predominantly male population. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: Common Chemical Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Frovatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of frovatriptan have not been established for cluster headache, which is present in an older, predominantly male population. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Product Label : Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Product Label: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Naratriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of naratriptan have not been established for cluster headache, which is present in an older, predominantly male population. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Rizatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of rizatriptan have not been established for cluster headache, which is present in an older, predominantly male population. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Sumatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of sumatriptan have not been established for cluster headache, which is present in an older, predominantly male population. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: Common Chemical Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Topiramate inhibits carbonic anhydrase isozymes such as CA II (35), CA IV (35, 36), and CA V (37). Topiramate has also been shown to inhibit both the fast and persistent components of sodium currents in neocortical cells (38). In addition, the drug may inhibit L-type calcium channels (39, 40). Topiramate also inhibits inward currents at some subtypes of kainate and AMPA glutamate receptors (41, 42). Finally, the drug may act as a histone deacetylase inhibitor (43). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS in the prescribing information). Safety and effectiveness of zolmitriptan have not been established for cluster headache, which is present in an older, predominantly male population. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
References:
1. Graham GG, Scott KF.
Mechanism of action of paracetamol.
Am J Ther. 2005 Jan-Feb;12(1):46-55. [Abstract]
2. Daya S, Anoopkumar-Dukie S.
Acetaminophen inhibits liver trytophan-2,3-dioxygenase activity with a concomitant rise in brain serotonin levels and a reduction in urinary 5-hydroxyindole acetic acid.
Life Sci. 2000 Jun 8;67(3):235-40. [Abstract]
3. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN.
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83. [Full Text]
4. Ouellet M, Riendeau D, Percival MD.
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14583-8. [Full Text]
5. Fredholm, Bertil B., IJzerman, Adriaan P., Jacobson, Kenneth A., Klotz, Karl-Norbert, Linden, Joel
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Pharmacol Rev 2001 53: 527-552 [Full Text]
6. Lindaman BA, Hinkhouse MM, Conklin JL, Cullen JJ.
The effect of phosphodiesterase inhibition on gallbladder motility in vitro.
J Surg Res 2002 Jun 15;105(2):102-8 [Abstract]
7. Bou J, Domenech T, Puig J, Heredia A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM.
Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.
Eur J Pharmacol. 2000 Dec 20;410(1):33-41. [Abstract]
8. Silberstein SD.
The pharmacology of ergotamine and dihydroergotamine.
Headache. 1997;37 Suppl 1:S15-25. [Abstract]
9. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL.
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
Circulation. 2000 Dec 5;102(23):2836-41. [Full Text]
10. Sanchez-Lopez A, Centurion D, Vazquez E, Arulmani U, Saxena PR, Villalon CM.
Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.
Br J Pharmacol. 2003 Oct;140(4):725-35. [Abstract]
11. Boess FG, Monsma FJ Jr, Meyer V, Zwingelstein C, Sleight AJ.
Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.
Mol Pharmacol. 1997 Sep;52(3):515-23. [Full Text]
12. Boess FG, Martin IL.
Molecular biology of 5-HT receptors.
Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317. [Abstract]
13. Roth BL, Kroeze WK, Patel S, Lopez E.
The Multiplicity of Serotonin Receptors: Uselessly diverse molecules or an embarrasment of riches?
The Neuroscientist. 2000. 6:252-262. [PDSP Ki database]
14. Pauwels PJ, Palmier C, Dupuis DS, Colpaert FC.
Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state.
Naunyn Schmiedebergs Arch Pharmacol. 1998 May;357(5):490-9. [Abstract]
15. Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL.
Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation.
Eur J Pharmacol. 1998 Jul 3;352(1):117-24. [Abstract]
16. Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L.
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
Br J Pharmacol. 2003 Sep;140(2):277-84. [Abstract]
17. Kalkman HO, Schneider F.
Effects of ergotamine and dihydroergotamine on 5-hydroxytryptamine-2A receptors in the isolated rat aorta.
Pharmacology. 1996 Dec;53(6):351-5. [Abstract]
18. McCarthy BG, Peroutka SJ.
Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175).
Headache. 1989 Jul;29(7):420-2. [Abstract]
19. Yamashita H, Kawakami H, Zhang YX, Tanaka K, Nakamura S.
Effect of amino acid ergot alkaloids on glutamate transport via human glutamate transporter hGluT-1.
J Neurol Sci. 1998 Feb 18;155(1):31-6. [Abstract]
20. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS.
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen
J Biol Chem. 2001 Sep 28;276(39):36734-41. [Full Text]
21. Ueda Y, Willmore LJ.
Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis.
Exp Brain Res 2000 Aug;133(3):334-9 [Abstract]
22. Johannessen CU.
Mechanisms of action of valproate: a commentatory.
Neurochem Int. 2000 Aug-Sep;37(2-3):103-10. [Abstract]
23. Vreugdenhil M, Wadman WJ.
Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis.
Epilepsia 1999 Nov;40(11):1512-22 [Abstract]
24. Loscher W.
Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
CNS Drugs 2002;16(10):669-94 [Abstract]
25. Cutrer FM.
Antiepileptic drugs: how they work in headache.
Headache. 2001 Nov-Dec;41 Suppl 1:S3-10. [Abstract]
26. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R.
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [Abstract]
27. Comer MB.
Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan.
Headache. 2002 Apr;42 Suppl 2:S47-53. [Abstract]
28. Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR.
Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor.
Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33. [Abstract]
29. Jahnichen S, Glusa E, Pertz HH.
Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.
Naunyn Schmiedebergs Arch Pharmacol. 2005 Jan;371(1):89-98. [Abstract]
30. Boers PM, Donaldson C, Zagami AS, Lambert GA.
Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy.
Cephalalgia. 2004 Feb;24(2):99-109. [Abstract]
31. Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL.
Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation.
Eur J Pharmacol. 1998 Jul 3;352(1):117-24. [Abstract]
32. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN.
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. [Abstract]
33. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ.
The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Br J Pharmacol. 2001 Aug;133(7):1029-34. [Abstract]
34. van den Broek RW, Bhalla P, VanDenBrink AM, de Vries R, Sharma HS, Saxena PR.
Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization.
Cephalalgia. 2002 Mar;22(2):83-93. [Abstract]
35. Dodgson SJ, Shank RP, Maryanoff BE.
Topiramate as an inhibitor of carbonic anhydrase isoenzymes.
Epilepsia 2000;41 Suppl 1:S35-9 [Abstract]
36. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT.
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
J Med Chem. 2002 Jan 17;45(2):312-20. [Abstract]
37. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT.
Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies.
Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [Abstract]
38. Taverna, S., Sancini, G., Mantegazza, M., Franceschetti, S., Avanzini, G.
Inhibition of Transient and Persistent Na+ Current Fractions by the New Anticonvulsant Topiramate
J Pharmacol Exp Ther 1999 288: 960-968 [Full Text]
39. Zhang X, Velumian AA, Jones OT, Carlen PL.
Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate.
Epilepsia. 2000;41 Suppl 1:S52-60. [Abstract]
40. Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G.
Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy.
Neuropharmacology. 2004 May;46(6):865-78. [Abstract]
41. Poulsen CF, Simeone TA, Maar TE, Smith-Swintosky V, White HS, Schousboe A.
Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons.
Neurochem Res. 2004 Jan;29(1):275-82.Neurochem Res. 2004 Jan;29(1):275-82. [Abstract]
42. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA.
Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.
Epilepsia. 2000;41 Suppl 1:S10-6. [Abstract]
43. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M.
The activity of antiepileptic drugs as histone deacetylase inhibitors.
Epilepsia. 2004 Jul;45(7):737-44. [Abstract]
44. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, Honey AC, Giles H, Moncada S.
Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Br J Pharmacol. 1997 May;121(2):157-64. [Abstract]
45. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR.
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Full Text]